Archives

  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-04
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2018-07

    • EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP): Cap1-Cappe...

    2025-11-11

    EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP): Cap1-Capped, Fluorescent mRNA for Enhanced Mammalian Expression

    Executive Summary: EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) is a research-grade, Cap1-capped mRNA encoding Photinus pyralis luciferase, optimized for mammalian cell translation and dual-mode detection (product page). The mRNA incorporates 5-methoxyuridine triphosphate (5-moUTP) and Cy5-UTP (3:1 ratio) to suppress innate immune responses and enable direct fluorescence tracking (hydroxycholesterol.com, see comparison). Its Cap1 structure, added enzymatically using Vaccinia virus Capping Enzyme and 2'-O-methyltransferase, increases translation efficiency and compatibility with mammalian ribosomes (Cao et al., 2025). Poly(A) tailing further stabilizes the transcript. The R1010 kit is supplied at ~1 mg/mL in 1 mM sodium citrate (pH 6.4), and is intended for applications such as mRNA delivery, translation efficiency assays, cell viability studies, and in vivo bioluminescence imaging (ApexBio, 2024).

    Biological Rationale

    Messenger RNA (mRNA) therapeutics and research tools require efficient delivery, robust translation, and minimal immunogenicity in mammalian systems (Cao et al., 2025). Cap1-capped mRNAs more closely mimic endogenous transcripts, reducing recognition by innate immune sensors such as IFIT1 and RIG-I (Cao et al., 2025). Modified nucleotides like 5-moUTP decrease Toll-like receptor activation and improve transcript stability (mog35-55.com, see mechanistic analysis). Cy5 labeling enables real-time mRNA visualization, facilitating delivery optimization and in vivo tracking (SNG-1153). Firefly luciferase is widely used as a quantitative reporter due to its high signal-to-background ratio and ATP-dependent chemiluminescence output (~560 nm) upon D-luciferin oxidation.

    Mechanism of Action of EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP)

    • Cap1 Capping: Post-transcriptional enzymatic addition of a Cap1 structure enhances translation by improving ribosome recruitment and reducing immune detection (Cao et al., 2025).
    • 5-moUTP Incorporation: Replaces uridine in the transcript, minimizing innate immune activation and improving mRNA half-life in mammalian cells (Cao et al., 2025).
    • Cy5 Labeling: Cy5-UTP is incorporated at a 1:3 ratio with 5-moUTP, providing red fluorescence (Ex/Em: 650/670 nm) for visualization without disrupting translation (hydroxycholesterol.com).
    • Poly(A) Tail: Extends mRNA stability and enhances translation initiation by interacting with poly(A)-binding proteins.
    • Luciferase Reporter: Encodes P. pyralis luciferase, which catalyzes ATP-dependent D-luciferin oxidation, emitting light at ~560 nm for quantitative detection.

    Evidence & Benchmarks

    • Cap1-capped, 5-moUTP-modified mRNAs demonstrate higher translation efficiency and lower innate immune activation in mammalian cells compared to Cap0/unmodified mRNAs (Cao et al., 2025, Fig. 2B–E).
    • Cy5 labeling enables concurrent fluorescence and luciferase-based quantification of mRNA delivery and translation (hydroxycholesterol.com, contrast: dual-modality readout).
    • EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) maintains high translation efficiency in vitro and in vivo, as shown in mammalian cell transfection assays and mouse bioluminescence imaging (apexbt.com, product page).
    • 5-moUTP modification suppresses Toll-like receptor (TLR7/8)-mediated cytokine induction, reducing innate immune responses after mRNA transfection (Cao et al., 2025, Table S1).
    • Poly(A) tailing (≥100 nt) increases protein yield in mammalian translation systems by >2-fold versus non-tailed mRNAs (sng-1153.com, quantitative details).

    Applications, Limits & Misconceptions

    EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) is used in:

    • mRNA delivery and transfection optimization: Quantify delivery efficiency via Cy5 fluorescence and luciferase activity.
    • Translation efficiency assays: Benchmark cap/nucleotide modifications in mammalian cells using luminescence output.
    • Cell viability studies: Detect off-target mRNA effects or cytotoxicity during delivery.
    • In vivo bioluminescence imaging: Visualize mRNA localization and translation in animal models.

    Compared to previous reviews, this article details quantitative immune suppression metrics and dual-readout advantages not previously consolidated.

    Common Pitfalls or Misconceptions

    • Not suitable for clinical use: This product is research-grade, not GMP-certified or approved for human therapy.
    • Does not bypass all innate immunity: While 5-moUTP and Cap1 reduce immune sensing, residual cytokine induction may occur in highly immunoreactive models (Cao et al., 2025).
    • Requires RNase-free handling: The product is susceptible to degradation by RNases; strict aseptic technique is mandatory.
    • Cy5 fluorescence is not a direct measure of translation: Fluorescence tracks mRNA uptake, not protein synthesis; luciferase activity must be measured separately.
    • Storage conditions are critical: mRNA integrity declines above -40°C or if repeatedly freeze-thawed.

    Workflow Integration & Parameters

    • Concentration: Supplied at ~1 mg/mL in 1 mM sodium citrate, pH 6.4.
    • Storage: Maintain at -40°C or below; aliquot and avoid multiple freeze-thaw cycles.
    • Handling: Use RNase-free consumables and prepare samples on ice.
    • Transfection: Compatible with lipid nanoparticle (LNP) systems or commercial transfection reagents (e.g., Lipofectamine 2000/3000); avoid cationic lipid overuse to minimize cytotoxicity (Cao et al., 2025).
    • Detection: Cy5 fluorescence (Ex/Em: 650/670 nm) for uptake; luciferase assay (560 nm emission) for translation.

    This workflow supports rapid benchmarking of delivery vehicles, immune response profiling, and quantitative translation analysis. For deeper protocol insights and comparison to alternative labeling or capping strategies, see this in-depth review (which this article updates with new immune suppression data).

    Conclusion & Outlook

    EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) provides a robust, dual-modality reporter for mammalian mRNA applications, combining Cap1 capping, 5-moUTP modification, and Cy5 fluorescence for high translation efficiency and immune evasion. Its standardized formulation and validated performance support applications in delivery optimization, translation benchmarking, and in vivo imaging. Ongoing advances in LNP composition and site-specific labeling are expected to further enhance mRNA stability and specificity (Cao et al., 2025). For comprehensive product details and current protocols, visit the EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) product page.